Truist upgraded pain therapy developer Pacira BioSciences (NASDAQ:PCRX) to Hold from Sell on Thursday, noting that the ...

Truist Securities upgraded Pacira Pharmaceuticals (NASDAQ:PCRX) stock rating from Hold to Buy, significantly raising the price target to $25.00 from the previous $8.00. The stock, currently trading at ...

Net interest margin, which measures lending profitability, expanded to 3.07%, compared with 2.95% a year earlier. Truist's ...

Money from the program will be used by nonprofit groups to help rebuild small businesses, housing and infrastructure in 39 ...

Leaders at the bank, which has been operating in DFW for more than a decade, want to capitalize on positive trends.

Influence Media Partners (“Influence Media” or “Influence”) — a leading music and entertainment company focused on partnering with and investing in to ...

Truist Financial's Q4 beat EPS and revenue estimates, but noninterest expenses rose and specific lending segments faced ...

Truist Securities analyst Jake Bartlett reiterated a Buy rating on the shares of Sysco Corp (NYSE:SYY) and lowered the price ...

Truist Financial analyst Youssef Squali maintained a Buy rating on Cimpress (CMPR – Research Report) today. The company’s shares closed ...

Truist initiated coverage of Tronox (TROX) with a Buy rating and $17 price target The firm believes Tronox has one of the “strongest ...

Truist Financial Corp. continued to settle into its trimmer fee-income strategy during the fourth quarter by slightly ...